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Innovative Therapies in the Management of  
Neonatal Respiratory Distress at Thomas Jefferson 
University Hospital 
Thomas Jefferson University Hospital (TJUH) was the first Delaware Valley hospital to 
provide extracorporeal membrane oxygenation (ECMO) in 1985. This innovative 
therapy for treatment of severe neonatal respiratory failure has improved the 
chances of survival for these infants from less than 20% to greater than 80%, a 
dramatic reversal in outcome. Jefferson's experience with this therapy is one of the 
largest in the country and the overall survival rates here (approximately 84%) are 
higher than the national average. Jefferson has continued to pursue innovations in 
ECMO techniques and procedures in an effort to further enhance the survival rate for 
these infants. Some of these new developments include: l) provision of better blood 
flow via a reconstruction of the right carotid artery, a technique pioneered by 
Jefferson pediatric surgeon Philip J. Wolfson, MD; 2) use of venovenous ECMO, a 
technique which completely spares the infant from the need for right carotid artery 
catheterization; and 3) participation in a national evaluation of the concomitant use 
of exogenous lung surfactant and ECMO, a procedure which could decrease the 
duration (and thus long-term consequences) of ECMO therapy.  
Because of the highly specialized nature of this therapy, Jefferson has actively 
negotiated with many Delaware Valley hospitals for referral of infants who require 
the special services of its intensive care nursery (ICN), where ECMO is provided. The 
quality of services provided by Jefferson's ICN and neonatal physicians have resulted 
in the ability of the unit to negotiate a pre-approved rate for ECMO hospitalization 
with many third-party payors. This rate, developed through TJUH's finance office, 
further enables Jefferson to attract infants with these specialized needs.  
Two additional, though experimental, approaches to the management of infants with 
neonatal respiratory distress are also underway at Jefferson. TJUH is now one of five 
medical centers in the US participating in an FDA evaluation of liquid ventilation 
utilizing perfluorochemical liquids to more closely approximate the fluid-filled 
conditions of lungs before birth. Another technique, ventilation with a mixture of 
oxygen and nitric oxide (NO), is also undergoing evaluation at Jefferson. The goal is 
for both of these techniques to be attempted in infants prior to using ECMO. Both are 
less invasive and, if successful, may provide a way to avoid the use of ECMO 
completely. Jefferson physicians hold Investigation New Drug exemptions for both of 
these techniques.  
Of interest to neonatologists and others in the health care community are the clinical 
outcomes of infants who as neonates have respiratory compromise or other risk 
factors for neurologic damage. Clinical outcomes are being evaluated for these 
infants at Jefferson via two multi-year NIH funded projects. The division of pediatric 
neurology, under the direction of Leonard J. Graziani, MD, and the high risk follow-up 
clinic, under the direction of Shobhana A. Desai, MD, follow these infants at Jefferson 
to better understand the long-term effects of these lifesaving techniques. The 
ultimate goal of all of these techniques is to provide the greatest chance for survival, 
recovery, and normal growth and development to these extremely high risk infants.  
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